Another study showed that treatment of human pancreatic cancer cell lines with the HDAC inhibitor TSA and the flavonoid silibinin led to a downregulation of Bcl-xL, which was accompanied by inhibition of CDK1 [36]. The gene discussed is CDK1; the disease is familial pancreatic carcinoma.